Why the study?
There have been no previous studies investigating the clinical effect of ticagrelor dose reduction as part of a de-escalation strategy.
Does a de-escalation strategy of reduced-dose ticagrelor and early aspirin discontinuation reduce net adverse clinical events compared to standard dual antiplatelet therapy in East Asian patients with acute myocardial infarction?
Does a de-escalation strategy of reduced-dose ticagrelor and early aspirin discontinuation reduce net adverse clinical events compared to standard dual antiplatelet therapy in East Asian patients with acute myocardial infarction?
The ongoing EASTYLE trial will determine whether a hybrid de-escalation strategy of reduced-dose ticagrelor and early aspirin discontinuation improves net clinical outcomes in East Asian patients with acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Leaves open optimal DAPT de-escalation in East Asian AMI; EASTYLE will test hybrid reduced-dose ticagrelor plus early aspirin discontinuation.
The EASTYLE study is currently ongoing, based on the hypothesis that ticagrelor reduction and a 3-month aspirin removal strategy (Hybrid De-escalation) as part of the de-escalation strategy can reduce cardiovascular complications (net clinical outcome).There have been no previous studies on the reduction effect of ticagrelor, and this study involves 35 sites in Korea, showing a registration rate of around 20% currently.Registration is expected to close in early or mid 2025, and results are anticipated to be announced around the same time as the ELECTRA-SIRIO 2 study.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: